1) Allred DC, Harvey JM, Berardo M, et al : Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11 : 155─168, 1988
2) 佐藤賢一郎,水内英充,北島義盛,他 : 閉経後に増大した脂肪平滑筋腫の1例.臨婦産65 : 731─736, 2011
3) Andersen J, Barbieri RL : Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Investig 2 : 663─672, 1995
4) Bulun SE, Lin Z, Imir G, et al : Regulation of aromatase expression in estrogen-responsive breast and uterine disease : from bench to treatment. Pharmacol Rev 57 : 359─383, 2005
5) 村上 節 : エストロゲンと疾患 子宮筋腫.日本臨床64 : 364─369, 2006
6) Schwartz LB, Rutkowski N, Horan C, et al : Use of transvaginal ultrasonography to monitor the effects of tamoxifen on uterine leiomyoma size and ovarian cyst formation. Ultrasound Med 17 : 699─703, 1988
7) Ang WC, Farrell E, Vollenhoven B : Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas : a literature review. Climacteric 4 : 284─292, 2001
8) Bayya J, Minkoff H, Khulpateea N : Tamoxifen and growth of an extrauterine leiomyoma. Eur J Obstet Gynecol Reprod Biol 141 : 90─91, 2008
9) Ritchie AC : Boyd’s Textbook of Pathology. 9th ed, Vol II, pp1352. Lea and Febiger, Philadelphia, 1990